Novavax

Novavax is moving from direct commercialization to a technology-licensing platform and plans to license its saponin-based adjuvant Matrix‑M and nanoparticle protein technology to major pharma partners. The company received $800 million in upfront and milestone payments from Pfizer and Sanofi over the past three years, has identified additional near-term milestones of $200 million, and cut its cost base by 80–90%, extending its financial runway to more than two years. Novavax is targeting non-GAAP profitability in 2028 (requiring revenue > $150 million), sees significant potential for combined COVID‑flu vaccines and expanded oncology applications, and expects multiple upcoming catalysts from partner studies and proof-of-concept data. » Plus sur de.investing.com

Sanofi and Takeda have received approvals in the U.S., the EU and Japan for the Nuvaxovid formulation targeted at the SARS‑CoV‑2 variant XFG for the 2026–2027 vaccination season. The partners will handle distribution in their regions; Novavax will receive license fees and milestone payments tied to approvals without establishing its own sales infrastructure. Nuvaxovid is a protein-based vaccine using recombinant nanoparticle technology, is stored at 2–8 °C, and showed a good tolerability profile in a phase‑4 study. » Plus sur de.investing.com

Total Novavax option volume rose to 13,629 contracts by Friday. Call volume was 1,518 contracts (highest since April 18, 2024), put volume 12,111 contracts (highest since December 16, 2025). Two $8 puts dominated trading: 5,708 contracts expiring July 31, 2026 (open interest 91) and 5,675 contracts expiring July 17, 2026 (open interest 10,878). The stock fell 2.5% to $9.16. » Plus sur de.investing.com